Physician profile
Nicholas J Orme
NPI 1689674632
$500.49
in general payments reported to CMS, 2019-2025
15 companies · $50.80 in 2025
The $50.80 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.22 · 2021: $141 · 2022: $89.26 · 2023: $21.18 · 2024: $144 · 2025: $50.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $94.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $52.52 | 2022-2024 | Airsupra |
| Boston Scientific Corporation | $47.95 | 2020-2025 | General - Pain Management |
| Ultragenyx Pharmaceutical INC. | $45.70 | 2023-2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $41.25 | 2024 | |
| Allergan, INC. | $30.91 | 2020 | |
| Alexion Pharmaceuticals, INC. | $27.62 | 2022 | |
| Corcept Therapeutics | $26.16 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $26.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.25 | 2024 | Gvoke Hypopen |
| Eisai INC. | $21.23 | 2021 | |
| Medtronic, INC. | $18.15 | 2024 | Intellis Adaptivestim |
| Abbott Laboratories | $17.09 | 2021 | |
| Pfizer INC. | $14.37 | 2021 | |
| Scynexis, INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.